Amniotic Membrane Companies

Top Industry Leaders in the Amniotic Membrane Market

*Disclaimer: List of key companies in no particular orderLatest Amniotic membrane Companies Update

July 2023: Verséa Ophthalmics, LLC, a Tampa, Florida-based company that specializes in providing comprehensive ocular point-of-care diagnostic and therapeutic interventions, and Celularity Inc., a biotechnology firm developing placental-derived allogeneic cell treatments and biomaterial products, today announced that the two companies have signed into a special U.S. commercialization consensus in which Verséa Ophthalmics will distribute Celularity's BIOVANCE® and BIOVANCE® 3L Ocular products to assist with the treatment of ocular surface disease and ocular surgical uses. Severe ocular surface disease can be handled with BIOVANCE® 3L Ocular, an acellular solution made of three layers of amniotic membrane. The purpose of BIOVANCE® 3L Ocular as a barrier membrane is to maintain tissue plane boundaries and safeguard the underlying tissue.

Aug 2023: The Smith & Nephew UK Pensions Fund and Rothesay have finalized a £260 million buy-in agreement. Following earlier deals between the two in 2013, 2017, and 2022, the scheme is now underwritten by medical technology company Smith & Nephew UK. As a result, all scheme participants are now covered with Rothesay. This buy-in transaction is the most recent in a series of buy-in deals that Rothesay has announced this year, including a £1.4 billion buy-in with the Safeway Pension Scheme that guaranteed benefits to over 22,500 members, a £762 million agreement with Morrisons, and a £160 million buy-in with the Repsol Sinopec Pension and Life Scheme.List of Amniotic membrane Key companies in the market